Scarica l'app Stockscreener
2.15
1.83%
-0.04
Pre-mercato:
2.16
0.01
+0.47%
Protalix BioTherapeutics Inc. Borsa (PLX) Ultime notizie
PLX Technical Analysis & ETF Price Forecast - Intellectia AI
EBIT per share of Protalix Biotherapeutics, Inc. – SWB:PBDA - TradingView
PLX SEC FilingsProtalix Biother 10-K, 10-Q, 8-K Forms - stocktitan.net
PLX|Protalix Biotherapeutics Inc|Price:2.150|Chg%:-0.04 - TradingKey
MACD Signal: Is Protalix BioTherapeutics Inc a top pick in the sector2026 Trading Volume Trends & Weekly High Return Forecasts - baoquankhu1.vn
Protalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115 - MSN
MAK Capital, Michael Kaufman report 3.62M‑share PLX stake (PLX) - stocktitan.net
Aug Opening: What is Protalix BioTherapeutics Incs valuation compared to sector2026 Retail Activity & AI Based Trade Execution Alerts - baoquankhu1.vn
Volume Summary: Will Protalix BioTherapeutics Inc benefit from rising consumer demandPortfolio Risk Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Analyst Downgrade: Should I add Protalix BioTherapeutics Inc stock to my portfolio2026 Top Gainers & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance (NYSE:PLX) - Seeking Alpha
HC Wainwright Issues Negative Outlook for PLX Earnings - MarketBeat
Zacks Research Has Bullish Estimate for PLX FY2026 Earnings - marketbeat.com
Can Protalix BioTherapeutics Inc lead its sector in growth2026 Growth vs Value & Weekly Top Gainers Alerts - baoquankhu1.vn
If You Invested $1,000 in Protalix Biother (PLX) - Stock Titan
A Look At Protalix BioTherapeutics (PLX) Valuation After Elfabrio Dosing Approval And Updated 2026 Revenue Guidance - Sahm
Research Analysts Issue Forecasts for PLX FY2026 Earnings - MarketBeat
Stock Market Recap: Is Cirrus Logic Inc forming a bullish divergenceRate Hike & High Win Rate Trade Alerts - baoquankhu1.vn
PLX: HC Wainwright & Co. Reiterates Buy Rating with $12 Target | - GuruFocus
Protalix BioTherapeutics (NYSE:PLX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Protalix BioTherapeutics (PLX) TTM Loss Challenges Bullish Profitability Narratives After FY 2025 Results - simplywall.st
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlig - GuruFocus
PLX: 2025 Full Year Results - Yahoo Finance
Protalix BioTherapeutics (PLX) Misses Earnings Estimates, Projec - GuruFocus
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results - Finviz
Protalix: Overview of Fourth Quarter Financial Results - Bitget
Protalix (PLX) 2025 10-K details Elfabrio expansion and PRX-115 gout program - Stock Titan
Protalix BioTherapeutics 2025 Annual Report: Innovative Plant Cell-Based Therapeutics, Pipeline, Intellectual Property, and Regulatory Overview - Minichart
Earnings call transcript: Protalix misses EPS, beats revenue in Q4 2025 By Investing.com - Investing.com South Africa
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 - Yahoo Finance
PLX: EU approval of Elfabrio's four-week dosing drives revenue growth and strengthens cash position - TradingView
Earnings call transcript: Protalix misses EPS, beats revenue in Q4 2025 - Investing.com
Recap Report: Can Protalix BioTherapeutics Inc keep up with sector leaders2026 Technical Overview & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Protalix BioTherapeutics Financial Results: Quarterly & Annual ReportNews and Statistics - IndexBox
Protalix BioTherapeutics 2025 10-K: $52.7M Revenue, $(6.6)M Net Loss - TradingView
PLX: 2025 revenue reached $52.7M with a net loss of $6.6M as R&D spending increased sharply - TradingView
Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results - TradingView
Protalix: Q4 Earnings Snapshot - marketscreener.com
PLX: 2025 net loss of $6.6M on $52.7M revenue; 2026 revenue outlook $78–83M with pipeline progress - TradingView
Protalix reports FY2025 results: $52.7M revenue, $6.6M net loss, Q2 2026 EU dosing approval - TradingView
Protalix (PLX) swings to 2025 net loss as R&D spend climbs and assets grow - Stock Titan
Earnings Preview: PLX to Report Financial Results Pre-market on March 18 - 富途牛牛
Protalix BioTherapeutics Earnings Announcement Scheduled - Intellectia AI
Can Protalix BioTherapeutics Inc sustain its profitabilityMarket Trend Summary & AI Driven Price Forecasts - baoquankhu1.vn
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 - Finviz
Rare-disease drug maker Protalix sets 2025 financial results call for March 18 - Stock Titan
Small cap wrap: Medicus Pharma, C3 Metals, Protalix BioTherapeutics… - Proactive Investors
European Commission Approves Once-Every-Four-Weeks Elfabrio® (Pegunigalsidase Alfa) Dosing for Fabry Disease, Reducing Treatment Burden for Adults - Minichart
EC approves new Elfabrio dosing regimen - The Pharma Letter
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen - Proactive Investors
Protalix Biotherapeutics Experiences Valuation Adjustment Amid Strong Market Performance Indicators - Markets Mojo
Chiesi Global Rare Diseases and Protalix BioTherapeutics - GlobeNewswire
Protalix Gains EU Approval for Extended Elfabrio Dosing - TipRanks
Protalix: European Commission approves 2 mg/kg every-4-weeks dosing for Elfabrio - TradingView
EU approves new Elfabrio dosing; Protalix (NYSE: PLX) earns $25M - Stock Titan
EU approves four-week dosing option for Chiesi and Protalix's Elfabrio - marketscreener.com
European Commission Approves New Dosing for Protalix (PLX) Elfab - GuruFocus
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) - The Manila Times
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):